Lyell Immunopharma
LYEL
106 hedge funds and large institutions have $180M invested in Lyell Immunopharma in 2023 Q3 according to their latest regulatory filings, with 16 funds opening new positions, 46 increasing their positions, 21 reducing their positions, and 9 closing their positions.
275% more call options, than puts
Call options by funds: $15K | Put options by funds: $4K
119% more repeat investments, than reductions
Existing positions increased: 46 | Existing positions reduced: 21
78% more first-time investments, than exits
New positions opened: 16 | Existing positions closed: 9
7% more funds holding
Funds holding: 99 → 106 (+7)
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
0.01% less ownership
Funds ownership: 2.45% → 2.44% (-0.01%)
54% less capital invested
Capital invested by funds: $389M → $180M (-$209M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
+$1.68M |
| 2 |
State Street
Boston,
Massachusetts
|
+$1.52M |
| 3 |
TD Asset Management
Toronto,
Ontario, Canada
|
+$1.15M |
| 4 |
BlackRock
New York
|
+$804K |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
+$666K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$3.5M |
| 2 |
MCMU
MIC Capital Management (UK)
London,
United Kingdom
|
-$3.13M |
| 3 |
FCMI
Foresite Capital Management IV
Larkspur,
California
|
-$2.17M |
| 4 |
Goldman Sachs
New York
|
-$281K |
| 5 |
Morgan Stanley
New York
|
-$229K |
LYEL Hedge Fund Activity: Q3 2023 in Review
106 of the 6,310 institutional investors tracked by Wall St. Rank reported a position in Lyell Immunopharma (LYEL) for Q3 2023, worth a combined $180M — down 54% from $389M a quarter earlier.
Buyers outnumbered sellers: 16 funds opened new LYEL positions and 9 closed out — a net gain of 7 holders — while 46 added to existing stakes and 21 trimmed.
The largest buyer was Citadel Advisors, adding an estimated $1.68M. The largest seller was T. Rowe Price Associates, cutting an estimated $3.5M.
- 106 institutional investors held Lyell Immunopharma (LYEL) as of Q3 2023, up from 99 in Q2 2023.
- Funds reported $180M of Lyell Immunopharma stock for Q3 2023, down 54% quarter-over-quarter.
- 16 funds opened new Lyell Immunopharma positions in Q3 2023 and 9 closed out, a net change of +7 holders.
- The largest Lyell Immunopharma buyer in Q3 2023 was Citadel Advisors, an estimated $1.68M added.
- The largest Lyell Immunopharma seller in Q3 2023 was T. Rowe Price Associates, an estimated $3.5M sold.
Based on aggregated 13F filings for Q3 2023.